Financial conflicts of interest in Japanese obstetrics and gynaecology clinical practice guidelines

Murayama, Anju; Miyazawa, Keishi; Kamamoto, Sae; Shigeta, Haruki; Kugo, Hinari; Higuchi, Kenichi; Senoo, Yuki

doi:10.1002/ctd2.273

Cited by 5 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the publication dates of the CPGs between 2019 and 2020, these financial relationships likely occurred during the development of the CPGs. This high percentage of authors receiving personal payments aligns with findings from other specialties within Japan, 12-15 17-22 31 33 38-42 where the proportion of CPG authors with personal payments ranged from 66.0% in obstetrics and gynaecology 42 to 96.3% in otolaryngology.…”

Section: Open Accesssupporting

confidence: 76%

Cross-sectional analysis of pharmaceutical industry payments to authors of clinical practice guidelines for bipolar disorder and major depressive disorder in Japan

Murayama,

Kugo,

Senoo

2024

BMJ Open

Self Cite

View full text Add to dashboard Cite

ObjectiveClinical practice guidelines (CPGs) are essential for standardising patient care based on evidence-based medicine. However, the presence of financial conflicts of interest (COIs) among CPG authors can undermine their credibility. This study aimed to examine the extent and size of COIs among authors of psychiatry CPGs in Japan.MethodsThis cross-sectional analysis of disclosed payments from pharmaceutical companies assesses the prevalence and magnitude of personal payments for lecturing, consulting and writing to CPGs for bipolar disorder and major depressive disorder in Japan between 2016 and 2020.ResultsThis study found that 93.3% of authors received payments over a 5-year period, with total payments exceeding US$4 million. The median payment per author was US$51 403 (IQR: US$9982–US$111 567), with a notable concentration of payments among a small number of authors, including the CPG chairperson. Despite these extensive financial relationships, only a fraction of authors disclosed their COIs in the CPGs. These large amounts of personal payments were made by pharmaceutical companies manufacturing new antidepressants and sleeping aids listed in the CPGs.ConclusionsThis study found that more than 93% of authors of CPGs for major depressive disorder and bipolar disorder in Japan received considerable amounts of personal payments from the pharmaceutical industry. The findings highlight deviations from international COI management standards and suggest a need for more stringent COI policies for psychiatry CPGs in Japan.

show abstract

Section: Open Accesssupporting

confidence: 76%

Cross-sectional analysis of pharmaceutical industry payments to authors of clinical practice guidelines for bipolar disorder and major depressive disorder in Japan

Murayama,

Kugo,

Senoo

2024

BMJ Open

Self Cite

View full text Add to dashboard Cite

show abstract

“…The high prevalence (77.2%) of financial ties to drug companies for non-research purposes among the authors in this study aligns with many previous studies in Japan, albeit with higher percentages. [3][4][5][6][7][8][9]13,41,42,[44][45][46][47][48] This could indicate a vulnerability to financial COI among the influential breast cancer experts in Japan. For example, the author previously reported that the proportions of authors accepting payments from drug companies were 66.0% in obstetrics and gynecology, 13 88% in nephrology, 5 88.2% in gastroenterology, 3,45 88.6% in urology, 46 90.6% in dermatology, 47 91.3%-100% in rheumatology, 4,41 87.0%-91.9% in infectious diseases, 6,44 94.4% in cardiology, 48 94.6% in hematology, 9 95.6% in a diabetes CPG, 42 96.3% in otolaryngology 7 and 100% in a CPG for hepatitis C treatment.…”

Section: Discussionmentioning

confidence: 99%

“…1,2 However, compiling evidence suggests that the financial conflicts of interest (COIs) between drug companies and the CPG authors potentially compromise the credibility of the guidelines. [3][4][5][6][7][8][9][10][11][12][13] These concerns jeopardise the trust in drug companies and draw attention. 1,2,5,[14][15][16][17][18] Given the profound impact of CPGs on patients, clinicians and various stakeholders, and their perception as guiding principles for physicians, 19 rigorous COI management strategies, encompassing minimisation of COIs among authors and guideline-producing societies, full disclosure of financial COIs and the appointment of COI-free CPG chairs, are indispensable.…”

Section: Introductionmentioning

confidence: 99%

Pharmaceutical company payments to Japanese breast cancer practice guideline authors

Murayama,

Higuchi,

Byreddy

et al. 2024

Clinical and Translational Dis

Self Cite

View full text Add to dashboard Cite

BackgroundThe creation of breast cancer practice guidelines requires proper management of financial relationships with drug companies, as they can introduce conflicts of interest (COIs) among guideline authors. However, little is known about the specific landscape and fraction of financial interactions between the authors of the Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, edition 2022 (JBCS2022) and drug companies.MethodsUsing payment data publicly disclosed by major drug companies in Japan, this study analysed the personal payments made to the authors of JBCS2022 between 2016 and 2020. We performed descriptive analyses on the payment data.ResultsOf the 149 JBCS2022 authors, 115 (77.2%) received at least one personal payment totaling $3 828 455 from drug companies between 2016 and 2020. The average and median payment amounts per author were $25 772 (standard deviation: $58 197) and $2761 (interquartile range: $322‒$15 828), respectively. The total annual payments per JBCS2022 authors between 2016 and 2019 increased from $588 054 in 2016 to $967 802 in 2019. The JBCS2022 chairperson and vice‐chairperson received $246 936 (fourth highest) and $216 744 (fifth highest) over the 5 years. More than 60% of personal payments to the JBCS2022 authors were not declared by the authors as they were below the declaration threshold set by the Japanese Breast Cancer Society. However, nine authors undeclared personal payments summing $594 615 even though these payments were higher than the thresholds.ConclusionThis study demonstrated that the majority of the breast cancer guideline authors received personal payments from drug companies in Japan. Furthermore, the majority of payments were not declared because of the less transparent COI policy.

show abstract

“… 2 , 4 , 82 , 83 , 84 , 85 , 86 Our study, however, has repeatedly demonstrated that nearly all Japanese CPG authors across specialties received significant payments for activities like delivering lectures and consulting services, leading to direct income. 3 , 5 , 18 , 22 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 87 , 88 , 89 , 90 , 91 Although the authors acknowledge the importance of collaboration between physicians and the health care industry in improving patient care, it is imperative to develop trustworthy and evidence‐based CPGs without establishing a group where >94% of the experts have substantial financial ties to the pharmaceutical industry.…”

Section: Discussionmentioning

confidence: 99%

“…Although many international and national professional societies producing CPGs have actively worked on minimizing financial COIs among CPG authors and mitigating the unfavorable influence of the industry on CPG recommendations, 2 , 4 , 19 , 20 , 21 , 22 , 23 the issue of widespread COIs among CPG authors remains an urgent problem in Japan. 5 , 18 , 24 , 25 , 26 , 27 , 28 , 29 We previously reported that 88% of chronic kidney disease CPG authors had financial COIs with the pharmaceutical industry in 2022. 18 Harada et al found that 95% of hematology CPG authors received personal payments between 2015 and 2017.…”

mentioning

confidence: 99%

Conflicts of Interest Among Cardiology Clinical Practice Guideline Authors in Japan

Murayama,

Aizawa,

Byreddy

et al. 2024

JAHA

Self Cite

View full text Add to dashboard Cite

Background Clinical practice guidelines (CPGs) offer disease management recommendations based on scientific evidence. However, financial conflicts of interest between CPG developers and the pharmaceutical industry could bias these recommendations, potentially affecting patient care. Proper management of these conflicts of interest is particularly crucial for maintaining the integrity of CPGs. The study aimed to evaluate the extent of financial relationships between the pharmaceutical industry and authors of CPGs for cardiovascular diseases in Japan. Methods and Results The study analyzed personal payments from the pharmaceutical industry to authors of cardiovascular disease CPGs published by the Japanese Circulation Society from January 2015 to December 2022. Payment data, including speaking, consultancy, and writing fees from 2016 to 2020, were extracted from a publicly available database containing personal payments disclosed by all major pharmaceutical companies. A total of 929 unique authors from 37 eligible Japanese Circulation Society CPGs were identified. Notably, 94.4% of these authors received personal payments from pharmaceutical companies, totaling >US $70.8 million. The mean±SD payment per author was US $76 314±138 663) and the median payment per author was US $20 792 (interquartile range: US $4262–US $76 998) over the 5‐year period. Chairs of CPGs received significantly higher payments than other authors. More than 80% of authors in each CPG received personal payments. Conclusions The study elucidated that there were considerable financial relationships between pharmaceutical companies and cardiology CPG authors in Japan. This finding deviates from international conflict of interest management policies, suggesting the need for more stringent conflict of interest management strategies by the Japanese Circulation Society to ensure the development of trustworthy and evidence‐based CPGs.

show abstract

Financial conflicts of interest in Japanese obstetrics and gynaecology clinical practice guidelines

Cited by 5 publications

References 11 publications

Cross-sectional analysis of pharmaceutical industry payments to authors of clinical practice guidelines for bipolar disorder and major depressive disorder in Japan

Cross-sectional analysis of pharmaceutical industry payments to authors of clinical practice guidelines for bipolar disorder and major depressive disorder in Japan

Pharmaceutical company payments to Japanese breast cancer practice guideline authors

Conflicts of Interest Among Cardiology Clinical Practice Guideline Authors in Japan

Contact Info

Product

Resources

About